Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Forty Seven
Biotech
Gilead ends blood cancer development of troubled CD47 med
Gilead is ending another late-stage study of magrolimab in leukemia after an “increased risk of death” was observed in a trial for the med.
Annalee Armstrong
Feb 7, 2024 10:59am
Gilead's magrolimab once again placed on partial clinical hold
Aug 21, 2023 9:50am
Bitterroot Bio emerges from stealth with $145M series A
Jun 7, 2023 8:00am
Investors fork out $76M for piece of Pheast's cancer therapies
Apr 26, 2022 11:00am
Gilead's $4.9B oncology bet hit with partial clinical hold
Jan 26, 2022 7:20am
Gilead taps brakes on $4.9B bet after rival's failure
Oct 29, 2021 7:30am
